Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child.
The Food and Drug Administration licensed a live-virus varicella vaccine (Varivax; Merck & Co Inc, West Point, PA) in March 1995. Prelicensure adverse events were minimal; however, since licensure and increased vaccine use, rare previously undetected risks have arisen. Presented here is the clinical course of a previously undiagnosed, human immunodeficiency virus-infected boy who developed dissemination of the vaccine strain of varicella zoster after immunization. chickenpox, human immunodeficiency virus, pneumonia, encephalopathy, varicella vaccine, adverse events, dissemination.
Kramer
J M
JM
Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
LaRussa
P
P
Tsai
W C
WC
Carney
P
P
Leber
S M
SM
Gahagan
S
S
Steinberg
S
S
Blackwood
R A
RA
D002644:Chickenpox / Q000209:etiology* / Q000517:prevention & control* / Q000821:virology; D019433:Chickenpox Vaccine / Q000009:adverse effects*; D015658:HIV Infections / Q000150:complications* / Q000276:immunology; D014645:Herpesvirus 3, Human / Q000254:growth & development / Q000276:immunology*; D006801:Humans; D007106:Immune Sera / Q000009:adverse effects; D016867:Immunocompromised Host / Q000276:immunology*; D007223:Infant; D008297:Male; D014611:Vaccination / Q000009:adverse effects*; D014613:Vaccines, Attenuated / Q000009:adverse effects*
D019433:Chickenpox Vaccine; D007106:Immune Sera; D014613:Vaccines, Attenuated; C030799:varicella-zoster immune globulin